CLINICAL_TRIALS
trial_result
· 2019-03-08
Clinical Trial Update: Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly [Phase 2]
Summary
Phase 2 clinical trial of BIM23B065 given as repeated subcutaneous injections in subjects with acromegaly; the study is terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Acromegaly | Phase 2 | Status: TERMINATED | Results posted: 2019-03-08